Bringing the p53 signature into focus

Cancer

Volumn 116, Issue 22, 2010, Pages 5119-5121

  Crum, Christopher P ^a   Xian, Wa ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53;

BREAST CANCER; CELL CYCLE ARREST; DNA DAMAGE; DNA METHYLATION; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GENOTOXICITY; GYNECOLOGIC CANCER; HUMAN; OVARY CANCER; PELVIS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; UTERINE TUBE CARCINOMA;

DNA REPLICATION; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; HUMANS; MUTATION; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78449288685     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25450     Document Type: Review

References (17)

1. National Cancer Institute. SEER Cancer Statistics Review, 1975-2005. Bethesda, Md: National Cancer Institute; 2005. Available at:. Accessed April 20, 2009.
2. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006; 100: 58-64.
3. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol. 2005; 106: 1327-1334.
4. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007; 25: 3985-3990.
5. Paley PJ, Swisher EM, Garcia RL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol. 2001; 80: 176-180.
6. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008; 26: 4160-4165.
7. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007; 31: 161-169.
8. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL,. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002; 94: 1365-1372.
9. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001; 195: 451-456.
10. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007; 211: 26-35.
11. Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H,. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009; 22: 1133-1138.
12. Kobel M, Huntsman D, Gilks CB,. Critical molecular abnormalities in high-grade serous carcinoma of the ovary [serial online]. Expert Rev Mol Med. 2008; 10: e22.
13. Norquist BM, Garcia RL, Allison KH, et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and mutations. Cancer. 2010; 116: 5261-5271.
14. Xian W, Miron A, Roh M, et al. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal fallopian tube. J Pathol. 2010; 220: 17-23.
15. Reedy MB, Hang T, Gallion H, Arnold S, Smith SA,. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis. Gynecol Oncol. 2001; 81: 441-446.
16. Widschwendter M, Apostolidou S, Jones AA, et al. HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. Int J Cancer. 2009; 125: 2214-2218.
17. Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, Monte N, Quade BJ, McKeon FD, Yassin Y, Xian W, Crum CP,. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol. 2010 May 21. [Epub ahead of print].